Compare Direxion NASDAQ 100 Equal Weighted Index Shares (QQQE) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Direxion NASDAQ 100 Equal Weighted Index Shares vs BIO-TECHNE Corp — how do they compare? Direxion NASDAQ 100 Equal Weighted Index Shares trades at $121.19 (market cap $1.47B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 7.7× Direxion NASDAQ 100 Equal Weighted Index Shares's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Direxion NASDAQ 100 Equal Weighted Index Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion NASDAQ 100 Equal Weighted Index Shares for 47 Days and BIO-TECHNE Corp for 63 Days on average.
| QQQE | TECH | |
|---|---|---|
Market Cap | $1.47B | $11.37B |
Volume | 181,648 | 3,153,511 |
Sector | Broad Market / Factor | Health |
52-Week High | $124.69 | $72.61 |
52-Week Low | $96.06 | $43.31 |
Typical Hold Time | 47 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QQQE (Direxion NASDAQ-100 Equal Weighted Index ETF) trades at $121.89, down 0.89% on the day. The ETF maintains a bullish technical outlook with strong moving average signals while oscillators show neutral momentum. Recent analysis highlights QQQE's advantage over traditional NASDAQ-100 ETFs due to its equal-weight approach, reducing technology concentration from 60% to 45% while maintaining exposure to large-cap growth stocks.
The equal-weight methodology provides diversification benefits amid tech sector volatility. Key risks include market concentration in growth stocks and broader market sentiment shifts. Recent analyst commentary suggests tactical opportunities in equal-weight strategies for the coming year, though investors should monitor sector rotation trends.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Direxion NASDAQ 100 Equal Weighted Index Shares
QQQE is an ETF that seeks to track the performance of the NASDAQ-100 Equal Weighted Index. Unlike traditional market-capitalization-weighted indexes, this fund assigns equal weight to each of the 100 non-financial companies in the NASDAQ-100 and rebalances quarterly. This equal-weighting scheme reduces concentration risk in the largest technology companies and increases the fund's exposure to smaller-cap and mid-cap companies within the index, providing a differentiated growth profile.
Read more on QQQE →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
